Al Ain, UAE – 30 June, 2026: Novo Nordisk, a global leader in the treatment of obesity and diabetes, signed a Memorandum of Understanding (MoU) with Al Ain Pharmacy Group, aimed at increasing awareness for obesity as a chronic disease, while engaging the public and healthcare professionals in Al Ain.     

As part of the MoU’s scope, the two parties organized the “Live Lighter™ in Al Ain” event at Hazza bin Zayed Stadium, Al Ain.  The event gathered several groups of stakeholders involved in obesity management to discuss this issue, with a particular focus on the Al Ain community.